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Abstract
Cadmium (Cd) is a heavy metal of considerable occupational and environmental concern affecting wildlife and
human health. Recent studies indicate that Cd, like other heavy metals, can mimic effects of 17β-estradiol (E2)
involving E2 receptor (ER) activation. Lactotrophs, the most abundant cell type in anterior pituitary gland, are the
main target of E2, which stimulates cell proliferation and increases prolactin secretion through ERα. The aim of this
work was to examine whether Cd at nanomolar concentrations can induce cell proliferation and prolactin release in
anterior pituitary cells in culture and whether these effects are mediated through ERs. Here we show that 10 nM Cd
was able to stimulate lactotroph proliferation in anterior pituitary cell cultures from female Wistar rats and also in GH3
lactosomatotroph cell line. Proliferation of somatotrophs and gonadotrophs were not affected by Cd exposure. Cd
promoted cell cycle progression by increasing cyclins D1, D3 and c-fos expression. Cd enhanced prolactin synthesis
and secretion. Cd E2-like effects were blocked by the pure ERs antagonist ICI 182,780 supporting that Cd acts
through ERs. Further, both Cd and E2 augmented full-length ERαexpression and its 46 kDa-splicing variant. In
addition, when co-incubated Cd was shown to interact with E2 by inducing ERα mRNA expression which indicates an
additive effect between them. This study shows for the first time that Cd at nanomolar concentration displays
xenoestrogenic activities by inducing cell growth and stimulating prolactin secretion from anterior pituitary cells in an
ERs-dependent manner. Cd acting as a potent xenoestrogen can play a key role in the aetiology of different
pathologies of the anterior pituitary and in estrogen-responsive tissues which represent considerable risk to human
health.
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Introduction
Cadmium (Cd) is a heavy metal that is dispersed throughout
the environment mainly as a result of pollution from industrial
and agricultural practices [1,2]. Asides from occupational
exposure, human intoxication results from consumption of
contaminated water and food or inhalation of cigarette smoke
[3]. Since Cd can not be degraded, the risk of environmental
exposure and contamination is constantly increasing because
of accumulation via both water and the food chain [2] and also
Cd long half-life (over 26 years) in the whole body in humans.
The reproductive health of humans and wild animals has
progressively deteriorated in the last 50 years [4]. It has been
suggested that environmental endocrine disruptors may play a
role in the aetiology of this pathology since the hypothalamic–
pituitary–gonadal axis is a target for many toxicants. Endocrine
disrupting chemicals (EDCs) are natural or synthetic
compounds that interfere in the biosynthesis, metabolism or
action of endogenous hormones. A particular class of EDCs,
called xenoestrogens (XEs), appears to trigger cell responses
normally induced by estrogens and therefore, thereby affecting
their signaling. Many chemicals in the environment can act as
endocrine active compounds [5]. Several reports show that Cd
possesses estrogen-like activity [6-9]. In the last decade, Cd
has also been shown to have potent estrogen- and androgen-
like activities in vivo and in vitro by directly binding to estrogen
and androgen receptors [10-12].
The major female hormone, 17β-estradiol (E2), is a key
regulator of pituitary physiology involved in hormone release as
well as proliferation and cell death in anterior pituitary gland
[13,14]. E2 exerts its effects through activation of multiple
genomic and non genomic signal pathways. Estrogen actions
are mediated by two specific intracellular estrogen receptors
(ERs), ERα and ERβ, belonging to the steroid/thyroid hormone
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superfamily of transcription factors [15]. Genomic signaling
takes place when ligands enter the cell and bind ER to induce
dimerization. ER dimers act as hormone-dependent
transcription regulators by directly binding DNA at estrogen
responsive elements (ERE) sequences or indirectly by
tethering to DNA through other transcriptions factors like Sp1
or AP-1 [16]. Non-genomic E2 actions involves rapid activation
of membrane-associated ERs which triggers second-
messenger signaling. This pathway mediates some E2 rapid
actions such as activation of nitric oxide synthesis and actin
cytoskeleton remodeling. Membrane-iniciated E2 actions are
not fully understood yet. To date, little is known about non-
genomic–dependent proliferation and hormone secretion. E2
stimulatory effects on prolactin secretion and lactotroph
proliferation are mediated by ERα Three forms of ERα have
been reported: the full-length 66 kDa ERα isoform (ERα66) and
two truncated splice variants (truncated estrogen receptor
products or TERPs) of 36 kDa (ERα36 or TERP1) and 46 kDa
(ERα46 or TERP2). These splice variants have been detected
first in the pituitary gland and then in other tissues including
breast, endometrium, smooth muscle cells and peripheral
blood mononuclear cells [17,18].
Anterior pituitary gland consists of several cell types
essential for many physiological processes such as growth,
development, homeostasis, metabolism, and reproduction.
Almost 50% of the gland is constituted by lactotrophs, which
secrete prolactin and, together with gonadotrophs, are the main
target of E2 actions on anterior pituitary.
Estrogens are one of the major regulators of anterior pituitary
physiology, eliciting a plethora of processes, including the
stimulation of lactotroph proliferation and up-regulation of
prolactin gene expression, synthesis, storage and release.
E2 regulation of target cell proliferation results from
promotion of both cell growth and survival [19]. This hormone
controls the function of several genes and proteins directly
involved in cell cycle regulation, including cyclins, proto-
oncogenes, and negative cell cycle regulators. Progression
through the cell cycle is strictly regulated by different proteins
such cyclins (A, B, D and E) associated to cyclin-dependent
kinases [20]. Several lines of evidence have linked estrogen
regulation of cell proliferation to cyclin D1 expression [21].
c-fos and c-jun proto-oncogenes are members of the AP-1
transcription factor that are rapidly induced by mitogenic stimuli
[22]. E2 was shown to stimulate c-fos expression in lactotrophs
and follicle-stellate cells [23].
Cd has been proposed to alter anterior pituitary secretion
through feedback mechanisms or by directly affecting anterior
pituitary cells [24,25]. Previous results from our group have
shown that Cd at micromolar concentrations induces oxidative
stress and decreases prolactin release both in vivo and in vitro
[3,26,27]. At the same time, Cd at nanomolar concentrations
displays estrogen-like activities in several E2-responsive cell
lines [7,28].
Most studies of Cd xenoestrogenic effects have been
performed on cell lines derived from different tumors. It has
been reported that Cd like E2 is able to stimulate cell
proliferation and induce the expression of E2-responsive genes
in MCF-7 breast cancer cell line [6,8]. Bearing in mind the
adverse effect of Cd on anterior pituitary and the role of this
gland in reproductive and normal endocrine function, the aim of
this study was to investigate whether Cd has estrogen-like
activities on anterior pituitary cells by addressing Cd effects on
anterior pituitary cell proliferation and prolactin secretion.
Materials and Methods
Ethics Statement
All experimental procedures were approved by the
Committee on Ethics of the School of Medicine (University of
Buenos Aires, Res. (CD) No. 2831/10) and were conducted in
compliance with the guidelines of the NIH Guide for the Care
and Use of Laboratory Animals.
Materials
CdCl2 (Cd) was purchased from Mallinckrodt Chemical
Works (St. Louis, MO, USA). Go Taq DNA polymerase,
random hexamers and dNTPs were provided by Promega
(Madison, WI, USA). TRIzol and molecular biology reagents
were from Invitrogen (Carlsbad, CA, USA). Media and reagents
for cell culture were purchased from Gibco (Rockville, MD,
USA) except for the fetal bovine serum and horse serum that
were obtained from GEN SA (Buenos Aires, Argentina). Cyclin
D1 and ERα antibodies were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Anti-recombinant rat
prolactin antiserum was provided by Dr. A. F. Parlow, National
Hormone and Pituitary Program, Torrance, CA, USA. Unless
otherwise indicated, all other reagents and antibodies were
obtained from Sigma-Aldrich (St. Louis, MO, USA).
Animals
Adult female Wistar rats (180-200 g) were used at random
stages of estrous cycle. Animals were kept in controlled
conditions of light (12:12 h light/dark cycle) and temperature
(21-24 °C). Food and water were supplied ad libitum.
Cell culture
Animals (8-10 per experiment) were killed by decapitation
and anterior pituitary glands without neural lobe were removed.
Cells were obtained from pooled anterior pituitary glands by
enzymatic (trypsin/DNase) and mechanical dispersion
(extrusion through a Pasteur pipette) as previously described
[29]. Cell viability was assessed by the trypan blue exclusion
method. In all cases, viability was greater than 90%. Dispersed
cells were seeded onto tissue culture plates and stabilized for
24 h (37 °C, 5% CO2 in air) in phenol red-free Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10%
charcoal-stripped fetal bovine serum (CSFBS), 10 µL/mL MEM
amino acids, 2 mM glutamine, 5.6 µg/mL amphotericin B and
25 µg/mL gentamicin (DMEM-S-10% CSFBS). For
immunocytochemistry experiments, cells were seeded on glass
coverslips in 24-well tissue culture plates (1.105 cells/well). For
mRNA and protein expression experiments, cells were seeded
in 6-well tissue culture plates (2.106 cells/well).
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Cell treatment
After the stabilization period (24 h), cells were synchronized
in free serum media for 24 h. Subsequently, they were
incubated for different times (8 to 96 h) with vehicle (control) or
10 nM Cd, with or without 100 nM ICI 182,780, an antagonist of
estrogen receptors (added 30 min before the treatments). E2 (1
nM) was used as positive control of the experiments.
GH3 cell culture
GH3 cells were cultured in F-12K Nutrient Mixture (Kaighn's
modification, GIBCO) supplemented with 15% horse serum,
2.5% fetal bovine serum, 1% penicillin/streptomycin and 0.1%
amphotericin B (pH 7.35; 37 °C, 5% CO2 in air). The incubation
medium was changed every 2 days. Cells were harvested once
per week by treatment with phosphate-buffered saline
containing trypsin (2.5 mg/mL; GIBCO), and reseeding was
carried out at 20% of the original density.
GH3 cells treatment
Cells were tripsinized, washed three times in serum free
media and seeded in DMEM-S-10% CSFBS. After the
stabilization period (24 h), cells were synchronized in free
serum media for 24 h. Cells were incubated with vehicle
(control) or 10 nM Cd for different times. E2 (1 nM) was used
as positive control of the experiments.
Immunocytochemistry (ICC)
Anterior pituitary cultures were incubated with 100 μM BrdU
24 h before the end of the treatment. GH3 cells were incubated
with 10μM BrdU 3 h before the end of the treatment. Cells were
fixed in 4% formaldehyde for 30 min at 4 °C, permeabilized
with 6N HCl in 1% Triton X-100 in PBS for 15 min at room
temperature and neutralized with 0.1 M sodium borate in 1%
Triton X-100 in PBS for 15 min at room temperature. Then,
cells were incubated in blocking solution (5% normal serum in
0.2% Triton X-100) for 2 h at room temperature. Cells were
incubated with mouse anti-BrdU primary antibody (1:200)
overnight at 4 °C and after three washes the secondary
antibody conjugated to fluorescein (1:250) was added. Cells
were mounted in anti-fade solution containing DAPI and
DABCO. Cells were observed and quantified in an Olympus
BX50 (Japan) fluorescence microscope. Data of at least 300
nuclei per triplicate obtained from random fields and from three
independent experiments were expressed as number of BrdU-
labeled cells / total cell number x 100.
After BrdU labeling, cells were incubated with guinea pig
primary antibodies (PRL, 1:2500; GH, 1:2000; LH: 1:2500) and
mouse anti-BrdU antibody (1:200) overnight at 4 °C. Then cells
were washed and incubated with secondary antibodies for 2 h
at 37 °C. Cells were mounted and counted as described above.
RNA isolation
177 μL of TRIzol reagent was added to each well. After
isolation, total RNA from tissues was spectrophotometrically
quantified at 260 nm. RNA integrity was checked by
formaldehyde/formamide gel electrophoresis.
RT and PCR reactions
First strand cDNA was synthesized with Moloney murine
leukemia virus (M-MLV) reverse transcriptase in buffer
containing 5.5 mM MgCl2, 0.5 mM dNTP, 2.5 μM random
hexamers, and 3.125 U/μL M-MLV reverse transcriptase.
Reactions were done in a final volume of 12 μL containing 1 μg
RNA. The reverse transcription reaction was run at 37 °C for 50
min and reverse transcriptase was inactivated by heating the
samples at 70 °C for 15 min before the PCR reactions. To
check for genomic contamination, the same procedure was
used on samples in a reaction solution lacking reverse
transcriptase.
Specific primers for the genes studied were checked with
Oligo Perfect designer software (Invitrogen) as detailed in
Table 1. GAPDH was used as endogenous control. Then,
samples were thermocycled for PCR amplification
(Mastercycler, Eppendorf, Hamburg, Germany). The reaction
mixture contained GoTaq PCR buffer, 1.5 mM MgCl2, 200 μM
of each dNTP, 0.625 U GoTaq polymerase and 300 nM of each
primer. We utilized RT-PCR methods to determine relative
changes in mRNA expression. Cycles of PCR amplification are
detailed in Table 2. Amplified products collected from various
cycles were analyzed by electrophoresis in 2% agarose-
ethidium bromide gels.
Analysis of semi-quantitative PCR data
The intensity of PCR products was determined by digital
image analysis using Gel Pro Analyzer (Media Cybernetics, LP,
Silver Spring, MD) software for Windows. For statistical
comparison of results from different experiments, data were
normalized to the value of the GAPDH amplified band in each
lane.
Preparation of cell homogenates for immunoblot
analysis
Anterior pituitary cells in culture were tripsinized and
sonicated in lysis buffer containing 50 mM HEPES pH 7.4, 150
mM NaCl, 1 mM EDTA, 0.1% SDS, 10 µg/mL leupeptin, 10
µg/mL pepstatin and 1 mM PMSF. Homogenates were
centrifuged for 20 min at 10,000 x g (4 °C) and the post-
mitochondrial fraction was used in the immunoblot analysis.
Protein measurement
Protein content of supernatants was measured by Bradford
reagent, using bovine serum-albumin as standard.
Immunoblot analysis
Fifty to eighty micrograms of total protein from each sample
was boiled for 5 min in Laemmli sample buffer and fractioned
on 10% SDS-PAGE. Resolved proteins were transferred to
polyvinylidene difluoride membranes and blocked for 2 days at
4 °C in blocking buffer (5% nonfat dry milk in 1% PBS). Then,
membranes were co-incubated overnight at 4 °C with rabbit
antisera anti-Cyc D1 (1:500) or ERα (1:500) or prolactin
(1:100000) together with anti-actin (1:1000) in blocking buffer.
Blots were washed and incubated for 1 h at room temperature
with horseradish-peroxidase conjugated goat antirabbit IgG
Cadmium Is Xenoestrogenic in Anterior Pituitary
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(1:2000), followed by detection of immunoreactivity with
diaminobenzidine solution containing 0.01% hydrogen
peroxide.
Analysis of immunoblot data
The intensity of immunoblot signals was determined by
digital image analysis using Gel Pro Analyzer software for
Windows. For statistical comparison of results from different
blots, levels were normalized to the value of the actin
immunoreactive band in each lane.
Hormone determination
Prolactin (PRL) was measured by a double antibody
radioimmunoassay (RIA) [30] using reagents provided by Dr.
A.F. Parlow (National Hormone and Pituitary Program,
Torrance, CA, USA). Recombinant prolactin (NIDDK-rPRL-
RP-3) was used as reference preparation and NIDDK-
antirPRL-S-9 as antiserum. The sensitivity of the assay was 0.1
ng/mL. Intra- and inter-assay coefficients of variation were
under 10%. To avoid inter-assay variations, all samples were
measured in the same assay. Prolactin level in control media at
8 h was 2825 ng/mL.
Statistical analysis
Results are expressed as mean ± SE and evaluated by one-
way ANOVA followed by Tukey’s, Dunnett’s or Student’s ‘t’
test, depending on the experimental design. Differences
between groups were considered significant if p<0.05. Results
were confirmed by at least three independent experiments.
Results
Cadmium stimulates anterior pituitary cell proliferation
Many authors have reported that E2 stimulates anterior
pituitary cell proliferation. To determine whether Cd affects
proliferation of these cells, primary cultures of anterior pituitary
cells were incubated with increasing concentrations of Cd
ranging from 10-12 M to 10-6 M for 96 h. Cell proliferation was
determined by BrdU incorporation into DNA. Since a significant
increase of cell proliferation was observed with 10 nM Cd
Table 1. Primers used for semi-quantitative RT-PCR assays.
Gene Primer Product size (bp)
Cyc D1 Forward 5' CGCCCTCCGTTTCTTACTTCA 3' 255
Cyc D1 Reverse 5' AACTTCTCGGCAGTCAGGGGA 3'  
Cyc D3 Forward 5' GCGTCCCCACCCGAAAGGCG 3' 386
Cyc D3 Reverse 5' TAGAGCAGGCACCCAGGCCT 3'  
ERα Forward 5' TCCACGATCAAGTTCACC 3' 311
ERα Reverse 5' GGATGTGGTCCTTCTCTT 3'  
PRL Forward 5' AGCCAAGTGTCAGCCCGGAAAG 3' 237
PRL Reverse 5' TGGCCTTGGCAATAAACTCACGA 3'  
c-fos Forward 5' CCAACTTTATCCCCACGGTGAC 3' 381
c-fos Reverse 5' TGGCAATCTCGGTCTGCAAC 3'  
GAPDH Forward 5' TGCACCACCAACTGCTTA 3' 176
GAPDH Reverse 5' GGATGCAGGGATGATGTTC 3'  
doi: 10.1371/journal.pone.0081101.t001
Table 2. PCR amplification schemes.
Gene Cycle number Scheme
  1 min, 94 °C
Cyc D1 and D3 50 (cyc D1) 1 min, 60 °C
 38 (cyc D3) 2 min, 72 °C
  30 sec, 95 °C
ERα 40 45 sec, 55 °C
  40 sec, 72 °C
  30 sec, 95 °C
PRL 38 60 sec, 56 °C
  45 sec, 72 °C
  30 sec, 94 °C
c-fos 42 30 sec, 60 °C
  45 sec, 74 °C
doi: 10.1371/journal.pone.0081101.t002
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treatment, this concentration was chosen for subsequent
studies. The growth rate induced by 10 nM Cd was very similar
to that observed with 1 nM E2 (BrdU incorporation %; Control:
23.8 ± 2.2; Cd: 45.5 ± 2.7**; E2: 45.5 ±4.8**; N=3. ANOVA
followed by Dunnett’s test, **p<0.01 vs. control).
Cadmium stimulates lactotroph proliferation
Anterior pituitary gland is constituted by a heterogeneous
secretory cell population, of which lactotrophs are one of the
main targets of E2 action.
To identify which pituitary cell type is affected by Cd
proliferative effects, specific antibodies against different
pituitary hormones such as PRL, GH and LH were used
followed by BrdU incorporation and DAPI staining. The ICC
study revealed that only lactotrophs showed an increase in
BrdU incorporation after 96 h of Cd treatment (Figure 1).
Somatotroph and gonadotroph cell numbers were unaffected
by either Cd or E2 exposure (data not shown).
Cadmium stimulates cyclin (Cyc) D1 and D3 and c-fos
gene expression
Cyclins and proto-oncogenes are directly involved in cell
cycle progression. To further confirm Cd proliferative effects in
anterior pituitary cells, we examined whether this metal is able
Figure 1.  Cadmium stimulates anterior pituitary lactotroph proliferation.  Anterior pituitary cells were treated with vehicle
(control), 10 nM Cd or 1 nM E2 for 96 h. Cell growth was determined by ICC measuring 24 h-BrdU incorporation. Lactotrophs were
identified by prolactin-specific antibody and cell nuclei were stained by DAPI. Pictures are representative of three independent
experiments performed in triplicate. Bars represent the mean ± SE of BrdU-labeling index expressed as positive BrdU lactrotroph /
total lactotroph cell number x100. ANOVA followed by Tukey-Kramer’s test, **p<0.001 vs. control (N=3).
doi: 10.1371/journal.pone.0081101.g001
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to induce Cyc D1, Cyc D3 and c-fos gene expression. Anterior
pituitary cultures were incubated with 10 nM Cd or 1 nM E2,
then mRNA levels of c-fos and Cyc D1 and D3 were
determined after 8-24 h or 72 h, respectively. Both Cd and E2
treatments were able to similarly increase Cyc D1, Cyc D3
(Figure 2A) and c-fos mRNA levels (Figure 2B). Cyc D1 protein
expression was also determined by western blot. Since the
antibody used is strongly cross-reactive with cyclin D2 and D3,
both of lower molecular weight, we only analysed the upper
band (approximately 38 kDa) corresponding to cyclin D1. We
observed a significant increase of cyclin D1 expression after
both Cd and E2 treatment (Figure 3). These results suggest
that Cd is able to reproduce E2 proliferative effects in anterior
pituitary cells.
Cadmium stimulates GH3 cell proliferation and Cyc D
expression
GH3 is a lactosomatotroph cell line derived from a rat E2-
responsive pituitary tumor. To further confirm the specific Cd
xenoestrogenic effect on lactotroph proliferation, we studied Cd
effects on GH3 cell proliferation.
After GH3 cells were incubated with 10 nM Cd or 1 nM E2,
cell proliferation and Cyc D1 and D3 mRNA expression were
measured. Cd treatment, like E2, was able to significantly
stimulate BrdU incorporation (Figure 4) and cyclin mRNA levels
(relative units as percent of control: Cyclin D1, control:
100±8.9; Cd: 135.4±2.6*; E2: 136±3.3*. Cyclin D3, control:
100±4.5; Cd: 118.3±1.6*; E2: 118.4±3.4*. ANOVA followed by
Tukey-Kramer’s test, *p<0.05 vs. control).
Cadmium increases prolactin synthesis and
secretion.  The stimulatory effect of E2 on prolactin secretion
is well known. To examine whether Cd mimics E2 action on
both prolactin synthesis and release, we measured prolactin
mRNA and protein expression and hormone levels in culture
media by PCR, western blot and RIA, respectively. Cd
treatment increased prolactin mRNA levels (Table 3), protein
expression (Figure 5) and hormone release over the times
studied (PRL release, fold of increase over respective control;
Figure 2.  Cadmium increases gene expression of proliferation markers in anterior pituitary cells.  Anterior pituitary cells
were treated with vehicle (control), 10 nM Cd or 1 nM E2. Gene expression was evaluated by PCR. Bars represent the mean ± SE
of densitometric values of cyclins D1 and D3 after 72 h (A) or c-fos after 8-24 h (B) normalized to GAPDH expression and are
expressed as percent of control. ANOVA followed by Tukey-Kramer’s test, *p<0.05, **p<0.001 vs. control (N=3).
doi: 10.1371/journal.pone.0081101.g002
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8 h: 1.5, 24 h: 3.0, 72 h: 4.4). Cd seems to affect prolactin
release in a time-dependent manner.
Estrogen receptor (ER) mediates cadmium effect on
Cyc D and PRL expression in anterior pituitary cells
E2/ERα pathway mediates cell proliferation and PRL
secretion in anterior pituitary gland. To determine whether the
effects of Cd were mediated by ERs, the ability of the pure ERs
antagonist ICI 182,780 (ICI) to block E2-like Cd effects was
tested. Anterior pituitary cells were first incubated with 100 nM
ICI for 20 min followed by incubation with or without Cd for 72
h. Expression of Cyc D1, D3 and prolactin mRNA was
evaluated by PCR. The antagonist had no effect by itself, but
when co-incubated with Cd, it was able to completely block Cd
effects on Cyc D1 and D3 (Figure 6A) and PRL mRNA levels
(Figure 6B) suggesting that Cd effects are mediated by ERs.
Cadmium modifies ERαexpression in anterior pituitary
cells
A variety of evidence indicates that E2 regulates the steady
state levels of ERα protein and mRNA. To examine Cd effects
on ERα expression, mRNA and protein levels were evaluated
by PCR and western blot, respectively.
Cd exposure enhanced ERα mRNA expression in anterior
pituitary cells at 8 and 24 h (Table 4). In parallel, Cd and E2
increased full-length ERα66 and the splicing variant ERα46 at
8 h (data not shown) and after 24 h of exposure (Figure 7). The
upper, unidentified immunoreactive bands were discarded. In
the same way, the splicing variant ERα36 was not included in
this analysis because it was only detected after E2 treatment.
Cadmium and E2 co-treatment has an additive effect on
ERα mRNA expression in anterior pituitary cells
Although there is evidence of interaction between Cd and
ERα Cd effects in the presence of E2 have been poorly
studied. To evaluate this condition, anterior pituitary cells were
incubated for 8 and 24 h with Cd, E2 or Cd plus E2, then
ERαmRNA expression was determined by PCR. Concording
with our previous results, both Cd and E2 per se increased
global ERα mRNA levels. Co-incubation of cells with Cd plus
E2 for 8 h also increased ERα mRNA expression, an effect
significantly higher than those observed with Cd or E2 alone,
suggesting an additive effect of Cd plus E2 on ERα expression
(Figure 8).
Discussion
Several reports have suggested that different environmental
contaminants may affect the endocrine system of wildlife
species and human life [31]. Many metals can act as endocrine
disruptors. In the present study, we showed for the first time
that Cd at nanomolar concentrations displayed xenoestrogenic
activities by affecting lactotroph proliferation and hormone
release from anterior pituitary cells. Cd has been implicated as
a cancer causing agent and has been classified by the
International Agency for Research on Cancer as a type I
human carcinogen [32]. Multiple evidence indicates that this
metal is able to act as an endocrine disruptor at micromolar
concentrations since it induces cell proliferation in cell lines
derived from breast, endometrium and prostate tumors [12,33].
Cd has shown a potent estrogen- and androgen-like activity
in vivo and in vitro by directly binding to estrogen and androgen
receptors [11]. However, specific mechanisms underlying the
Figure 3.  Cadmium increases cyclin D1 protein expression in anterior pituitary cells.  Anterior pituitary cells were treated with
vehicle (control), 10 nM Cd or 1 nM E2 for 72 h. A representative western blot is shown. Bars represent the mean ± SE of
densitometric values normalized to β-actin expression and are expressed as percent of control. ANOVA followed by Tukey-Kramer’s
test, *p<0.05 vs. control (N=3).
doi: 10.1371/journal.pone.0081101.g003
Cadmium Is Xenoestrogenic in Anterior Pituitary
PLOS ONE | www.plosone.org 7 November 2013 | Volume 8 | Issue 11 | e81101
effects of Cd as an endocrine disruptor remain to be
elucidated. The xenoestrogenic activity of Cd at submicromolar
concentrations has been reported in some cell lines, especially
tumor-derived cells [7,28]. Nevertheless, our study used
primary cultures of anterior pituitary cells and investigated
some parameters specifically involved in E2 action on this
gland: lactotroph proliferation and prolactin secretion. We also
Figure 4.  Cadmium stimulates GH3 cell proliferation.  GH3 cells were treated with vehicle (control), 10 nM Cd or 1 nM E2 for 96
h. Cell growth was determined by ICC measuring 3 h-BrdU incorporation. Cell nuclei were stained by DAPI. Pictures are
representative of three independent experiments performed in triplicate. Bars represent the mean ± SE of BrdU-labeling index
expressed as positive BrdU cells / total cell number x 100. ANOVA followed by Tukey-Kramer’s test, *p<0.05 vs. control (N=3).
doi: 10.1371/journal.pone.0081101.g004
Table 3. Cadmium stimulates prolactin mRNA expression.
 Rel units (% of control)
 Control Cd
8 h 100.0 ± 5.2 169.9 ± 18.3*
24 h 100.0 ± 9.0 180.3 ± 15.5**
72 h 100.0 ± 9.7 192.4 ± 13.2**
Anterior pituitary cells were treated with vehicle (control) or 10 nM Cd for 8, 24 or 72 h. Prolactin mRNA was determined by PCR. Densitometric values were normalized to
GAPDH expression and are expressed as mean ± SE. ANOVA followed by Tukey-Kramer’s test, *p<0.05, **p<0.01 vs. respective control.
doi: 10.1371/journal.pone.0081101.t003
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studied Cd effect on ERα expression and its role in Cd E2-like
effects.
Anterior pituitary gland is made up of heterogeneous cell
population of which nearly 50% are lactotrophs [34]. Cd effect
on proliferation of lactotrophs was observed, but not of
somatotrophs nor gonadotrophs. Other hormone-secretory
cells (thyrotrophs and corticotrophs) were not studied since
their percentage of the population (3%) and renewal rate are
very low. Remarkably, the stimulation grade of proliferation
caused by 10 nM Cd was analogous to that observed after 1
nM E2 treatment, suggesting that these cells are very sensitive
to this metal.
Diverse evidence has shown that Cd at micromolar
concentrations as well as other xenoestrogen compounds, are
able to stimulate proliferation of several human tumor cell lines
such as MCF-7 breast cancer cells [8,12,33] and LNCaP
prostate cells [35]. It has also been reported that some
xenoestrogens such as endosulphan and chlordane stimulate
prolactin secretion without affecting cell growth of the GH3
lactotroph cell line [36]. Our results show that nanomolar
concentrations of Cd also promote GH3 cell proliferation,
indicating that Cd is able to stimulate proliferation of not only
normal but also tumor cells.
The cell cycle is a finely tuned process whose progression is
strictly controlled by the expression and phosphorylation status
of specific proteins [37]. Cyclin Ds function as cell cycle
regulators modulating progression of cell through the G1/S
transition [38]. Other key components in the response to the
proliferative signal are the immediate-early c-fos and c-myc
genes, whose expression is rapidly induced by mitogenic
stimuli [22]. Proliferative E2 signaling through ERα involves up-
regulation of many of these genes [23,39]. Cd interaction with a
multitude of cell signal transduction pathways, many
associated with mitogenic signalling [40], has been widely
documented. Multiple evidence, both in vivo and in vitro, has
shown the potential of Cd to mimic estrogen effects at
micromolar concentrations in various tissues [6,7,41], and Cd
was demonstrated to activate ERα through interaction with the
receptor’s hormone-binding domain [6,7,12].
Here, we showed that 10 nM Cd exposure enhanced both
Cyc D1 and Cyc D3 expression in an ERα−dependent manner
in anterior pituitary cells. Further, c-fos mRNA expression was
also increased by Cd treatment. Similar to what was observed
in primary cultures, Cd stimulated Cyc D1 and Cyc D3 mRNA
expression in GH3 cells. Consequently, it is likely that the
increase of cyclins expression occurs mainly in the lactotroph
population since these cells showed augmented proliferation
after E2 or Cd treatment.
All together, these results show that Cd, at nanomolar
concentration, exerts a potent, ERs-dependent xenoestrogenic
effect on cell proliferation of both normal and tumor derivate
lactotrophs, indicating that these cells are highly receptive to
this metal.
Figure 5.  Cadmium increased 23 kDa prolactin (PRL) protein expression in anterior pituitary cells in culture.  Anterior
pituitary cells were incubated with 10 nM Cd or vehicle (control) for 8 h. Protein expression was measured by western blot. Bars
represent mean ± SEM of PRL densitometric values normalized to β-actin and are expressed as percent of control. **P<0.01,
Student’s ‘t’ test (N=3).
doi: 10.1371/journal.pone.0081101.g005
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Prolactin is a well-known estrogen-inducible gene [42].
Previous reports from our laboratory showed that Cd, at
micromolar concentrations, is cytotoxic and inhibits prolactin
release [26]. However, to our knowledge, no Cd
xenoestrogenic effect on this hormone has yet been reported.
The present study shows that Cd, at nanomolar concentration,
stimulates anterior pituitary prolactin secretion by increasing
prolactin mRNA expression and hormone release in ERs-
dependent manner. Rousseau et al. reported that nanomolar
concentrations of endosulphan, an organochlorine pesticide, as
well as chlordane, enhance prolactin mRNA expression in GH3
cells without affecting cell growth [36]. On the contrary, Wade
et al. showed that endosulphan does not affect prolactin
secretion in vivo [43]. Similarly to Cd, another related
Figure 6.  E2 receptors (ERs) mediates cadmium effect on cyclins D1 and D3 and PRL mRNA expression.  Anterior pituitary
cells cultures were first incubated with 100 nM ICI 182,780 (ICI) for 20 min and then incubated with vehicle (control) or 10 nM Cd for
72 h. Cyc D1 and D3 (A) and PRL (B) mRNA expression was evaluated by PCR. Bars represent the mean ± SE of densitometric
values normalized to GAPDH and are expressed as percent of control. ANOVA followed by Tukey-Kramer’s test, **p<0.01 vs.
control, ##p<0.01 vs. Cd (N=3).
doi: 10.1371/journal.pone.0081101.g006
Table 4. Cadmium modifies ERα mRNA expression in anterior pituitary cells.
 Rel units (% of control)
 Control Cd
8 h 100.0 ± 3.5 138.7± 9.6*
24 h 100.0 ± 5.1 141.6 ±2.0**
Anterior pituitary cells were treated with vehicle (control) or 10 nM Cd for 8 or 24 h. ERα mRNA was determined by PCR. Densitometric values were normalized to GAPDH
expression and are expressed as mean ± SE. ANOVA followed by Tukey-Kramer’s test, *p<0.05, **p<0.01 vs. respective control.
doi: 10.1371/journal.pone.0081101.t004
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compound, bisphenol-A, was shown to display potent
xenoestrogenic activity by modulating prolactin secretion both
in vivo and in vitro and by stimulating lactotroph proliferation
[44].
Figure 7.  Cadmium exposure increases ERα.  protein expression in anterior pituitary cells. Anterior pituitary cells were
treated with vehicle (control), 10 nM Cd or 1 nM E2 for 24h. A representative western blot is shown. Bars represent the mean ± SE
of densitometric values of full-length ERα (open bars) and ERα46 (black bars) normalized to β-actin expression and are expressed
as percent of control. ANOVA followed by Tukey-Kramer’s test, *p<0.05, **p<0.01, ***p<0.001 vs. respective control; #p<0.05,
###p<0.001 vs. Cd (N=3).
doi: 10.1371/journal.pone.0081101.g007
Figure 8.  Additive effect of cadmium and E2 co-treatment on ERα mRNA expression.  Anterior pituitary cell cultures were
treated with vehicle (control), 10 nM Cd or 1 nM E2 or 10 nM Cd plus 1 nM E2 for 8 h or 24 h. ERα mRNA expression was
evaluated by PCR. Bars represent the mean ± SE of densitometric values normalized to GAPDH. ANOVA followed by Tukey-
Kramer’s test, *p<0.05, p<0.01, p<0.001 vs. Control; #p<0.05 vs. Cd; ^p<0.05 vs. E2 (N=3).
doi: 10.1371/journal.pone.0081101.g008
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E2 is known to regulate its own receptor expression in
different tissues [17]. Here, we demonstrate that Cd was also
able to modulate mRNA expression of global ERα in anterior
pituitary cells. This expression was increased at 8 and 24 h. On
the other hand, Garcia-Morales et al. showed that higher Cd
concentrations (1 μM) decreased ERα mRNA levels after 24 h
treatment in MCF-7 cells [6].
Anterior pituitary cells express ERα protein of 66 kDa
(ERα66) and two TERPs, TERP1 and TERP2, corresponding
to ERα36 and ERα46, respectively [17]. Previous evidence
showed that E2 treatment was able to increase both TERPs’
mRNA levels while full-length ERα and ERβ remained
unchanged in anterior pituitary gland from ovariectomized rats.
Noticeably, both TERPs’ mRNA levels were found to increase
in Fischer 344 rats but only TERP1 was affected in anterior
pituitary cells from Sprague-Dawley rats [45]. Our results show
that 10 nM Cd, like E2, caused a marked increase of both full-
length ERα and TERP2 protein levels. However, our findings
do not tally with this previous evidence, mainly due to different
experimental designs. Here, we performed our experiments on
anterior pituitary cells in culture from Wistar rats at random
stages of estrous cycle while Mitchner et al. studied E2 effects
on anterior pituitary gland from ovariectomized Fisher 344 and
Sprague-Dawley rats. In concordance with our findings,
previous data showed that E2 treatment induces mRNA
expression of TERP2 in human macrophages in culture [46].
All together, this diverse evidence shows that E2-elicited ERα
regulation is cell type-, strain-, and species-specific.
In the present study we cannot differentiate between ERα
mRNA splicing variants since the primers were directed against
a common region of all ERα. However, it is likely that the
augmented ERα mRNA expression corresponds mainly to an
increase in TERPs as revealed after immunoblot analysis. We
also observed that Cd and E2 mildly induced ERα full-length
expression. To our knowledge, this is the first report to show
the up-regulation of ERα66 driven by its natural ligand which is
also reproduced by Cd in vitro. Since TERPs play a negative
role in E2 signaling per se and trough binding ERα [47], it is
likely that full-length ERα up-regulation does not participate in
this pathway. It is also possible that augmented full-length ERα
expression is a by-product of ERα mRNA splicing.
Cd xenoestrogenic effect on MCF-7 cells has been attributed
to its ability to activate ERα through interaction with the
hormone binding domain of the receptor [7]. Cadmium binds
with high affinity in a non-competitive way [48]. Cd interaction
with the receptor appeared to involve several amino acids in
the hormone-binding pocket of the receptor, suggesting that
this metal may form a coordination complex with the hormone
binding domain and thereby activate the receptor. Interaction of
Cd with ERs involves specifically cysteines 381 and 447,
glutamic acid 523, histidine 524, and aspartic acid 538 [7]. Few
studies have examined the possibility of an interaction between
E2 and different metals or xenoestrogens. Here we show that
simultaneous incubation with Cd and E2 had an additive effect
on ERα mRNA expression. This result is supported by previous
evidence showing that E2 exposure together with some metals
as copper, cobalt or lead at micromolar concentrations, results
in an additive effect on ERα mRNA and protein expression in
MCF-7 cells [8].
Here, we showed that potent Cd xenoestrogenic actions take
place at subtoxic, nanomolar concentrations in a relative short
period of time, which underscores its harmful potential. Dual
actions of Cd (proapoptotic or xenoestrogenic) depending on
its concentration raise concerns about the impact of this
environmental toxin on human health.
In sum, the present work shows for the first time that Cd can
display xenoestrogenic activities by inducing cell growth and
stimulating prolactin secretion from anterior pituitary cells.
Considering that prolactin is involved in the regulation of many
physiological processes such as growth, development,
metabolism and reproduction, the disruption of prolactin
secretion by Cd can play a pivotal role in fertility and
reproductive disorders associated with Cd contamination. Our
results support the hypothesis that, as a xenoestrogenic agent,
Cd can disrupt hormone status thus affecting reproductive
functions. Even further, Cd E2-like actions can be of major
importance in neoplastic processes in estrogen-dependent
tissues.
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